GNPX NASDAQ
Genprex, Inc.
1W: -5.4%
1M: -20.1%
3M: -54.2%
YTD: -54.5%
1Y: -94.3%
3Y: -100.0%
5Y: -100.0%
$0.82
+0.01 (+0.75%)
Weekly Expected Move ±11.2%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress2 trades
ETF Holdings—
Key Statistics
Market Cap$1.3M
52W Range0.74-55
Volume236,637
Avg Volume924,551
Beta-0.93
Dividend—
Analyst Ratings
Company Info
CEORyan Confer
Employees15
SectorHealthcare
IndustryBiotechnology
IPO Date2018-03-29
Websitegenprex.com
3300 Bee Cave Road
Austin, TX 78746
US
Austin, TX 78746
US
877 774 4679
About Genprex, Inc.
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Latest News
Top 3 Health Care Stocks That Are Set To Fly In Q2
Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer
Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
Congressman Who Was Top 2025 Stock Picker Buys Shares Of $5M Company You've Never Heard Of
Genprex Provides Clinical Update on Diabetes Gene Therapy Program
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| LONGNECKER BRENT M | S-Sale | 8 | $1.23 | 2026-04-14 |
| LONGNECKER BRENT M | S-Sale | 10 | $1.23 | 2026-04-14 |
| Berger Mark Stanley | F-InKind | 7,168 | $2.00 | 2026-02-27 |
| Confer Ryan M. | F-InKind | 9,330 | $2.00 | 2026-02-27 |
| Moreno Toscano Jose | A-Award | 9,000 | — | 2025-12-22 |